No products in the cart.
Pre-made Vibostolimab benchmark antibody ( Whole mAb, anti-TIGIT therapeutic antibody, Anti-VSIG9/VSTM3/WUCAM Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-620
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Vibostolimab biosimilar, Whole mAb, Anti-TIGIT Antibody: Anti-VSIG9/VSTM3/WUCAM therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Vibostolimab is a TIGIT-targeting (T-cell immunoreceptor with Ig) antibody is being developed by Merck Sharp & Dohme for the treatment of solid tumours such as non-small cell lung cancer, malignant melanoma.
| Products Name (INN Index) | Pre-Made Vibostolimab biosimilar, Whole mAb, Anti-TIGIT Antibody: Anti-VSIG9/VSTM3/WUCAM therapeutic antibody |
|---|---|
| INN Name | Vibostolimab |
| Target | TIGIT |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Merck |
| Conditions Approved | NA |
| Conditions Active | Solid tumours,Non-small cell lung cancer,Malignant melanoma |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | TIGIT |
| Package |
Previous slide
Next slide
